EVALUATE THE DOSE ADJUSTMENT OF NAS IN CHB PATIENT WITH RENAL IMPAIRMENT.
- At: 2015 FIP Congress in Düsseldorf (Germany)
- Type: Poster
- By: TING, Yuling (SiJhih Cathay General Hospital, Pharmacy, New Taipei City, China Taiwan)
- Co-author(s): Yu-Ling Ting
According to American association for the study of liver diseases (AASLD) 2009 Guidelines on Chronic Hepatitis B (CHB), the dosage of oral nucleoside or nucleotide analogues (NAs) should adjust when patient’s creatinine clearance (CrCl)<50ml/min.
We retrospectively collected all the prescriptions of NAs from November 1, 2013 to October 31, 2014... The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.